Epidemiology of Heart Failure with Preserved Ejection Fraction

Heart Failure Clinics

Volumn 10, Issue 3, 2014, Pages 377-388

  Andersson, Charlotte ^a,b,c   Vasan, Ramachandran S ^a,b  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Epidemiology; Heart failure; Mortality; Preserved ejection fraction; Prognosis

Indexed keywords

BIOLOGICAL MARKER;

AGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; OBESITY; PREVALENCE; PROGNOSIS; REVIEW; SEDENTARY LIFESTYLE; SLEEP DISORDERED BREATHING; AGED; CAUSE OF DEATH; FEMALE; HEART STROKE VOLUME; MALE; MIDDLE AGED; PHYSIOLOGY; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL; SYNDROME;

AGED; CAUSE OF DEATH; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL ANALYSIS; SYNDROME;

EID: 84903387554     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.04.003     Document Type: Review

References (72)

1. Cleland J.G., Pellicori P. Defining diastolic heart failure and identifying effective therapies. JAMA 2013, 309:825-826.
2. Vasan R.S., Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000, 101:2118-2121.
3. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
4. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:1810-1852.
5. Caruana L., Petrie M.C., Davie A.P., et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000, 321:215-218.
6. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
7. Maestre A., Gil V., Gallego J., et al. Diagnostic accuracy of clinical criteria for identifying systolic and diastolic heart failure: cross-sectional study. JEval Clin Pract 2009, 15:55-61.
8. Maurer M.S., King D.L., El-Khoury Rumbarger L., et al. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. JCard Fail 2005, 11:177-187.
9. Vasan R.S., Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996, 156:1789-1796.
10. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. JAm Coll Cardiol 2007, 50:768-777.
11. Vasan R.S., Benjamin E.J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. JAm Coll Cardiol 1995, 26:1565-1574.
12. Ceia F., Fonseca C., Mota T., et al. Prevalence of chronic heart failure in southwestern Europe: the EPICA study. Eur J Heart Fail 2002, 4:531-539.
13. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D.
14. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. NEngl J Med 2002, 347:305-313.
15. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
16. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012, 33:1750-1757.
17. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
18. Cleland J.G., Tendera M., Adamus J., et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
19. Chinali M., Joffe S.W., Aurigemma G.P., et al. Risk factors and comorbidities in a community-wide sample of patients hospitalized with acute systolic or diastolic heart failure: the Worcester Heart Failure Study. Coron Artery Dis 2010, 21:137-143.
20. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277.
21. Guder G., Frantz S., Bauersachs J., et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail 2009, 2:563-571.
22. Andersson C., Gislason G.H., Weeke P., et al. The prognostic importance of a history of hypertension in patients with symptomatic heart failure is substantially worsened by a short mitral inflow deceleration time. BMC Cardiovasc Disord 2012, 12:30.
23. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119:3070-3077.
24. Mogelvang R., Sogaard P., Pedersen S.A., et al. Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Copenhagen City Heart Study. Eur Heart J 2009, 30:731-739.
25. Hoffmann S., Jensen J.S., Iversen A.Z., et al. Tissue Doppler echocardiography improves the diagnosis of coronary artery stenosis in stable angina pectoris. Eur Heart J Cardiovasc Imaging 2012, 13:724-729.
26. Garcia-Fernandez M.A., Azevedo J., Moreno M., et al. Regional diastolic function in ischaemic heart disease using pulsed wave Doppler tissue imaging. Eur Heart J 1999, 20:496-505.
27. Nagueh S.F., Rao L., Soto J., et al. Haemodynamic insights into the effects of ischaemia and cycle length on tissue Doppler-derived mitral annulus diastolic velocities. Clin Sci (Lond) 2004, 106:147-154.
28. Lewis E.F., Solomon S.D., Jablonski K.A., et al. Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail 2009, 2:209-216.
29. Vaccarino V. Ischemic heart disease in women: many questions, few facts. Circ Cardiovasc Qual Outcomes 2010, 3:111-115.
30. Ho J.E., Lyass A., Lee D.S., et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013, 6:279-286.
31. Brouwers F.P., de Boer R.A., van der Harst P., et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013, 34:1424-1431.
32. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. JAm Coll Cardiol 2004, 43:317-327.
33. Mogensen U.M., Ersboll M., Andersen M., et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 2011, 13:1216-1223.
34. Bitter T., Faber L., Hering D., et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009, 11:602-608.
35. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JAm Coll Cardiol 2012, 59:998-1005.
36. Rijzewijk L.J., van der Meer R.W., Smit J.W., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. JAm Coll Cardiol 2008, 52:1793-1799.
37. Myasoedova E., Crowson C.S., Nicola P.J., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. JRheumatol 2011, 38:1601-1606.
38. Davis J.M., Roger V.L., Crowson C.S., et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 2008, 58:2603-2611.
39. Roman M.J., Salmon J.E. Cardiovascular manifestations of rheumatologic diseases. Circulation 2007, 116:2346-2355.
40. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355:260-269.
41. Maxwell C.B., Jenkins A.T. Drug-induced heart failure. Am J Health Syst Pharm 2011, 68:1791-1804.
42. Kane G.C., Karon B.L., Mahoney D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011, 306:856-863.
43. Lam C.S., Lyass A., Kraigher-Krainer E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011, 124:24-30.
44. Velagaleti R.S., Gona P., Pencina M.J., et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. Am J Cardiol 2014, 113:117-122.
45. Neeland I.J., Drazner M.H., Berry J.D., et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. JAm Coll Cardiol 2013, 61:187-195.
46. Cheng J.M., Akkerhuis K.M., Battes L.C., et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013, 15:1350-1362.
47. Go A.S., Mozaffarian D., Roger V.L., et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:143-152.
48. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
49. Lim S.S., Vos T., Flaxman A.D., et al. Acomparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
50. Steinberg B.A., Zhao X., Heidenreich P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012, 126:65-75.
51. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
52. Murad K., Kitzman D.W. Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. Heart Fail Rev 2012, 17:581-588.
53. Vasan R.S., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. JAm Coll Cardiol 1999, 33:1948-1955.
54. Henkel D.M., Redfield M.M., Weston S.A., et al. Death in heart failure: a community perspective. Circ Heart Fail 2008, 1:91-97.
55. Chan M.M., Lam C.S. How do patients with heart failure with preserved ejection fraction die?. Eur J Heart Fail 2013, 15:604-613.
56. Campbell R.T., Jhund P.S., Castagno D., et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. JAm Coll Cardiol 2012, 60:2349-2356.
57. Tribouilloy C., Rusinaru D., Mahjoub H., et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008, 29:339-347.
58. Somaratne J.B., Berry C., McMurray J.J., et al. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail 2009, 11:855-862.
59. Ntusi N.B., Mayosi B.M. Epidemiology of heart failure in sub-Saharan Africa. Expert Rev Cardiovasc Ther 2009, 7:169-180.
60. Dunlay S.M., Redfield M.M., Weston S.A., et al. Hospitalizations after heart failure diagnosis a community perspective. JAm Coll Cardiol 2009, 54:1695-1702.
61. Chen J., Normand S.L., Wang Y., et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 2011, 306:1669-1678.
62. Shah A.M., Shah S.J., Anand I.S., et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014, 7:104-115.
63. Solomon S.D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
64. Zile M.R., Gottdiener J.S., Hetzel S.J., et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011, 124:2491-2501.
65. Persson H., Lonn E., Edner M., et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. JAm Coll Cardiol 2007, 49:687-694.
66. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
67. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007, 115:1982-1990.
68. Maurer M.S., Burkhoff D., Fried L.P., et al. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. JAm Coll Cardiol 2007, 49:972-981.
69. He K.L., Burkhoff D., Leng W.X., et al. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions<55% versus 40% to 55% versus <40%. Am J Cardiol 2009, 103:845-851.
70. Gupta D.K., Shah A.M., Castagno D., et al. Heart failure with preserved ejection fraction in African-Americans - The Atherosclerosis Risk in Communities (ARIC) Study. JACC Heart Fail 2013, 1:156-163.
71. Klapholz M., Maurer M., Lowe A.M., et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. JAm Coll Cardiol 2004, 43:1432-1438.
72. Katz D.H., Beussink L., Sauer A.J., et al. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol 2013, 112:1158-1164.